A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy Clinical Trial

Official title:

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02644668
• Other study ID #: CY 5021
• Status: Completed
• Phase: Phase 2
• Start date: January 14, 2016
• Est. completion date: May 31, 2018

Study information

• Verified date: August 2020
• Source: Cytokinetics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).

Description:

CY 5021 is a Phase 2, double-blind, randomized, placebo-controlled, multiple dose study of reldesemtiv in 2 sequential ascending dose cohorts of patients with SMA. Patients will be randomized 2:1 to receive reldesemtiv or placebo twice daily for 8 weeks. Patients randomized to reldesemtiv in Cohort 1 will receive a dose of 150 mg twice daily and patients randomized to reldesemtiv in Cohort 2 will receive 450 mg twice daily. Within each cohort, randomization will be stratified by ambulatory status (ambulatory versus non ambulatory).

The primary objective of the study is to determine the PD effects of reldesemtiv on measures of pulmonary function, respiratory function, muscle strength, and motor function. Other PD measures include changes in the timed up and go (TUG) test, a 6-minute walk test (6MWT), and patient and investigator global assessments. Secondary objectives include the safety of multiple doses of reldesemtiv and an evaluation of the pharmacokinetics of reldesemtiv.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: May 31, 2018
• Est. primary completion date: May 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Able to comprehend and willing to sign an Informed Consent Form (ICF) for patients 18 years of age and older. For patients less than 18 years of age, parent(s)/legal guardian(s) of patients must provide written informed consent prior to participation in the study and informed assent will be obtained from minors at least 12 years of age when required by regulation.

• Males or females with genetically confirmed diagnosis of SMA who are Type II, III or IV and at least 12 years of age

• Ambulatory patients, once having achieved a standing position independently, must be able to complete at least one lap in the 6-minute walk test (at least 50 meters) within 6 minutes without assistance.

• Non-ambulatory patients (defined as individuals who are effectively requiring a wheelchair for all mobility needs; they may be able to stand or walk short distances, but unable to walk 50 meters without assistance in 6 minutes). Non-ambulatory patients must be able to tolerate an upright sitting position, with support, continuously for 3 hours

• Hammersmith (HFMS-E) score = 10 and = 54

• Contracture of the elbow flexion and knee flexion = 90 degrees

• Pre-study clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator

• Able to swallow an oral suspension and in the opinion of the Investigator, is expected to continue to be able to do so for the duration of the trial. Administration via a feeding tube is not allowed.

• Forced vital capacity (FVC) > 20% predicted

• Male patients who have reached puberty must agree to do either of the following from Screening until 10 weeks after the last dose of the investigational product unless they have had a vasectomy and confirmed sperm count is zero:

• Abstain from sexual intercourse, OR

• If having heterosexual intercourse, must use a condom and their female partners who are of childbearing potential must use a highly effective contraception method*

• Female patients who have had their first period will be considered of childbearing potential unless they are anatomically and physiologically incapable of becoming pregnant. If of childbearing potential, the female patients must:

• Have a negative urine/serum pregnancy test at Screening AND

• Abstain from heterosexual intercourse from Screening until 10 weeks after the last dose of investigational product OR

• If having heterosexual intercourse, must use a highly effective contraception method* and require the male partners to use a condom from Screening until 10 weeks after the last dose of investigational product

*Highly effective contraception methods include:

• Established use of oral, injected or implanted hormonal methods of contraception

• Placement of an intrauterine device (IUD) or intrauterine system (IUS)

• Male patients must agree to refrain from sperm donation from Screening until 10 weeks after the final study drug administration

Exclusion Criteria:

• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator

• Hospitalization within 2 months of Screening

• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be allowed)

• A clinically significant illness within 4 weeks of Screening

• History of alcoholism or drug addiction within 2 years prior to Screening

• History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to Screening

• Patient has used a strong CYP3A4 inhibitor within 7 days prior to first dose of study drug or a strong CYP3A4 inducer within 14 days prior to first dose of study drug

• Any other medical condition that would interfere with performance of testing including (but not limited to) significant joint pain or arthritis limiting mobility, and chronic neuromuscular pain sufficient to require ongoing analgesic medication

• Participation by two people at the same time that are living in the same household

• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or five half-lives of the other investigational study drug, whichever is greater, prior to Screening

• An ALT or AST greater than 2-fold the upper limit of normal (ULN) or has total bilirubin greater than the ULN at screening. These assessments may be repeated once at the investigator's discretion (within the screening window)

• Currently taking nusinersen, or has taken it in the past, or plans to take it during the course the study

Related Conditions & MeSH terms

• Atrophy
• Muscular Atrophy
• Muscular Atrophy, Spinal
• Spinal Muscular Atrophy

Intervention

Drug:
• Placebo
Granules for oral suspension (placebo)
• Reldesemtiv 150 mg
Granules for oral suspension, 18.7% reldesemtiv
• Reldesemtiv 450 mg
Granules for oral suspension, 56.0% reldesemtiv

Locations

Country	Name	City	State
Canada	Alberta Children's Hospital	Calgary	Alberta
Canada	Children's Hospital - LHSC	London	Ontario
Canada	Montreal Neurological Institute and Hospital	Montreal	Quebec
Canada	Children's and Women's Health Centre of British Columbia	Vancouver	British Columbia
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Johns Hopkins Hospital Institute for Clinical and Translational Research Pediatric Clinical Research Unit	Baltimore	Maryland
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Ann and Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	UCLA	Los Angeles	California
United States	Hospital for Special Care	New Britain	Connecticut
United States	University of California Irvine	Orange	California
United States	Nemours Childrens Hospital	Orlando	Florida
United States	Pediatric Neuromuscular Clinic Stanford University	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	The University of Utah, Clinical Neurosciences Center	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
Cytokinetics	Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Week 8 in Forced Vital Capacity (FVC)	FVC was measured using a calibrated spirometer (in units of liters). Patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs).	baseline and 8 weeks
Primary	Change From Baseline to Week 8 in Maximum Inspiratory Pressure (MIP)	MIP was measured (in units of cm H20) using a calibrated spirometer with an inspiratory pressure valve attached. For the test, patients were asked to inhale as forcefully as possible, to their maximum pressure.	baseline and 8 weeks
Primary	Change From Baseline to Week 8 in Maximum Expiratory Pressure (MEP)	MEP was measured (in units of cm H20) using a calibrated spirometer with an exspiratory pressure valve attached. For the test, patients were asked to maximally inhale then perform a forced exhalation with as forcefully as possible.	baseline and 8 weeks
Primary	Muscle Strength Mega-Score at Week 8	Muscle strength of 3 muscle groups (elbow flexion, knee extension, and shoulder abduction) were measured bilaterally using a hand-held dynamometer. Muscle strength was measured twice for each body location; if the variability between the 2 measures was > 15%, a third measure was obtained.; The maximum muscle strength of the 2 measurements was identified and transformed as a percent change from baseline using the equation: ([postbaseline value - baseline value] / baseline value) × 100.; The mega-score was a composite score that averaged strength across the 3 muscle groups. It was calculated as the mean of the non-missing transformed muscle strength scores among the 3 muscle groups each measure bilaterally (totaling 6 body locations).	baseline and 8 weeks
Primary	Change From Baseline to Week 8 in the Hammersmith Functional Motor Scale-Expanded (HFMS-E)	The HFMS-E evaluated the level of independent mobility and motor skills through assessment of 33 test-items, each scored from 0 (worse) to 2 (better). The total score was calculated as the sum of the scores among the 33 test items, and has a range from 0 to 66.	baseline and 8 weeks
Primary	Change From Baseline to Week 8 in Revised Upper Limb Module (RULM)	The RULM assessed motor function in the upper limbs (specifically shoulder, elbow, wrist, and hand function) that related to activities of everyday life. The RULM consisted of 20 items, 1 of which was scored on a 7-point scale (from 0 to 6), 18 were scored on a 3-point scale (from 0 to 2), and 1 was scored on a 2-point scale (0 or 1). The total score was the sum of each response and could range from a minimum of 0 to a maximum of 43 points. Higher scores reflected better motor function.	baseline and 8 weeks
Primary	Change From Baseline to Week 8 in the TUG Test	The TUG test measured the time (in seconds) it took for a patient to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down.	baseline and 8 weeks
Primary	Change From Baseline to Week 8 in the 6MWT	The 6MWT measured the distance (in meters) a patient walked in 6 minutes.	baseline and 8 weeks
Primary	Patient Global Assessment at the End of Week 8	Patients assessed whether they felt the same, better, or worse than prior to dosing on Day 1.	8 weeks
Primary	Investigator Global Assessment at the End of Week 8	The Investigator assessed whether patient appeared the same, better, or worse than prior to dosing on Day 1.	8 weeks
Secondary	Reldesemtiv Maximum Observed Plasma Concentration (Cmax)	Determined by evaluation of reldesemtiv plasma concentrations from blood samples collected prior to dosing and at 1, 3, and 6 hours following dosing	End of Week 8
Secondary	Reldesemtiv Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC0-12)	Determined by evaluation of reldesemtiv plasma concentrations from blood samples collected prior to dosing and at 1, 3, and 6 hours following dosing	End of Week 8